| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
HIF-1 alpha 556-574 targets hypoxia-inducible factor-1 (HIF-1) signaling pathways. HIF-1alpha is a transcription factor that forms a heterodimer with HIF-1beta and binds to hypoxia response elements (HREs) in the promoter regions of target genes. HIF-1alpha regulates the expression of numerous genes involved in angiogenesis (VEGF), glycolysis (GLUT1, LDHA), erythropoiesis (EPO), and cell survival. The peptide fragment (residues 556-574) may be involved in protein-protein interactions, degradation, or transactivation functions of HIF-1alpha. The peptide is used as a research tool to study HIF-1alpha-mediated signaling and oxygen sensing.
|
|---|---|
| ln Vitro |
In vitro, HIF-1 alpha 556-574 is used as a peptide fragment to study the structure, function, and interactions of HIF-1alpha. The peptide may be used in binding assays to identify interacting proteins or in structural studies to characterize the HIF-1alpha protein. HIF-1alpha functions as a master regulator of the response to oxygen homeostasis, and the peptide fragment may be involved in regulatory mechanisms. In cellular assays, the peptide may be used to study HIF-1alpha stability, degradation, or transcriptional activity. Hypoxia-induced gene expression is initiated when HIF-1alpha is stabilized in response to a lack of oxygen. The peptide is a valuable tool for studying oxygen sensing and hypoxia signaling.
|
| ln Vivo |
In vivo data for HIF-1 alpha 556-574 are limited as the peptide is primarily used as a research tool in in vitro experiments. Peptide fragments generally have limited in vivo utility due to poor stability, low bioavailability, and rapid clearance. The compound is intended for research use only and is not for human therapeutic applications. Researchers interested in in vivo applications should consult the primary literature for the most current information. The peptide is used to study HIF-1alpha-mediated signaling pathways in hypoxia, cancer, and ischemic diseases.
|
| Enzyme Assay |
In vitro binding assays for HIF-1 alpha 556-574 involve studying protein-protein interactions between the HIF-1alpha peptide fragment and its binding partners. The peptide can be labeled with biotin or a fluorescent tag for detection. Recombinant proteins (e.g., VHL, p300/CBP) are incubated with the peptide in assay buffer at 4degC for 1-4 hours. Bound complexes are captured on streptavidin-coated plates or beads and detected by ELISA, Western blotting, or fluorescence spectroscopy. Binding affinity (Kd) is determined from saturation binding curves. Competition assays with unlabeled peptide or mutated peptides are used to assess specificity.
|
| Cell Assay |
Cellular assays for HIF-1 alpha 556-574 are performed using cell lines such as HeLa, HEK-293, or cancer cells to study HIF-1alpha function. Cells are cultured under normoxic (21% O2) or hypoxic (1% O2) conditions. The peptide fragment may be delivered into cells using cell-penetrating peptides or lipofection. HIF-1alpha activity is assessed by measuring the expression of HIF-1alpha target genes (VEGF, GLUT1, LDHA) by qRT-PCR or Western blotting. HIF-1alpha protein levels are assessed by Western blotting under normoxic and hypoxic conditions. Luciferase reporter assays with HRE-containing promoters are used to measure HIF-1alpha transcriptional activity.
|
| Animal Protocol |
In vivo animal studies for HIF-1 alpha 556-574 are not typically performed, as the compound is used as a research tool for in vitro experiments. The peptide is not intended for administration to animals or humans. For in vivo studies of HIF-1alpha, researchers typically use small-molecule HIF inhibitors or activators, or genetic models. The peptide fragment is a biochemical reagent for laboratory use only.
|
| ADME/Pharmacokinetics |
HIF-1 alpha 556-574 (CAS#: 1201633-99-9) has molecular formula C101H1₅0D2N20O34S2 and molecular weight 2,256.54. The peptide consists of 19 amino acid residues derived from hypoxia-inducible factor-1 alpha (HIF-1alpha), corresponding to residues 556-574 of the full-length protein. HIF-1alpha is a transcription factor that functions as a master regulator of the cellular response to oxygen homeostasis. The peptide is used in research to study HIF-1alpha structure, function, and protein-protein interactions. Storage should be at -20degC. For research use only.
|
| References | |
| Additional Infomation |
HIF-1 alpha 556-574 (CAS#: 1201633-99-9) is a short peptide fragment consisting of 19 amino acid residues derived from hypoxia-inducible factor-1 alpha (HIF-1alpha), corresponding to residues 556-574 of the full-length protein. HIF-1alpha is a transcription factor that functions as a master regulator of the cellular response to oxygen homeostasis, regulating the expression of genes involved in angiogenesis, glycolysis, erythropoiesis, and cell survival. The peptide fragment is used in research to study HIF-1alpha structure, function, and protein-protein interactions. As of the current date, HIF-1 alpha 556-574 is not approved for clinical use.
|
| Exact Mass |
2256.038
|
|---|---|
| CAS # |
1201633-99-9
|
| Related CAS # |
HIF-1 alpha (556-574) (TFA)
|
| PubChem CID |
171042999
|
| Appearance |
White to off-white solid powder
|
| LogP |
-2.3
|
| Hydrogen Bond Donor Count |
26
|
| Hydrogen Bond Acceptor Count |
37
|
| Rotatable Bond Count |
71
|
| Heavy Atom Count |
157
|
| Complexity |
4950
|
| Defined Atom Stereocenter Count |
20
|
| SMILES |
[2H]C1CN([C@@H](C1[2H])C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)O)C(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)N
|
| InChi Key |
AIEACJWERUSQII-IOXQDZIYSA-N
|
| InChi Code |
InChI=1S/C101H152N20O34S2/c1-14-53(10)82(100(153)121-35-19-23-74(121)97(150)108-62(33-37-157-13)87(140)113-68(45-78(128)129)94(147)116-71(48-81(134)135)95(148)115-70(47-80(132)133)93(146)112-66(42-55-20-16-15-17-21-55)91(144)105-59(28-30-75(103)123)85(138)118-72(101(154)155)41-52(8)9)119-96(149)67(43-56-24-26-57(122)27-25-56)117-98(151)73-22-18-34-120(73)99(152)54(11)104-88(141)63(38-49(2)3)110-86(139)61(32-36-156-12)107-84(137)60(29-31-76(124)125)106-89(142)65(40-51(6)7)111-92(145)69(46-79(130)131)114-90(143)64(39-50(4)5)109-83(136)58(102)44-77(126)127/h15-17,20-21,24-27,49-54,58-74,82,122H,14,18-19,22-23,28-48,102H2,1-13H3,(H2,103,123)(H,104,141)(H,105,144)(H,106,142)(H,107,137)(H,108,150)(H,109,136)(H,110,139)(H,111,145)(H,112,146)(H,113,140)(H,114,143)(H,115,148)(H,116,147)(H,117,151)(H,118,138)(H,119,149)(H,124,125)(H,126,127)(H,128,129)(H,130,131)(H,132,133)(H,134,135)(H,154,155)/t53-,54-,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,71-,72-,73-,74-,82-/m0/s1/i18D,22D/t18?,22?,53-,54-,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,71-,72-,73-,74-,82-
|
| Chemical Name |
(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S,3S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-carboxypropanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-4-methylpentanoyl]amino]-4-carboxybutanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-methylpentanoyl]amino]propanoyl]-3,4-dideuteriopyrrolidine-2-carbonyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-4-methylsulfanylbutanoyl]amino]-3-carboxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-phenylpropanoyl]amino]-5-oxopentanoyl]amino]-4-methylpentanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~44.32 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (1.11 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
